Market Place
Sourcing Support
All News #Library
Rare Diseases
TransCon HGH Boosts TransCon CNP in Achondroplasia
08 Apr 2026 //
GLOBENEWSWIRE
Ascendis Launches Yuviwel with Orphan Drug Exclusivity in US
06 Apr 2026 //
GLOBENEWSWIRE
New Two-Year APPROACH Data Show Durable TransCon CNP Benefits
16 Mar 2026 //
GLOBENEWSWIRE
FDA Approves Once-Weekly YUVIWEL for Children with Achondroplasia
28 Feb 2026 //
GLOBENEWSWIRE
FDA Approve Once-Weekly Yuviwel for Children Aged 2 Years & Older
27 Feb 2026 //
GLOBENEWSWIRE
FDA Delays Decision On Ascendis` Dwarfism Prospect By 3 Months
26 Nov 2025 //
PRESS RELEASE
FDA Extends Review of TransCon CNP for Pediatric Achondroplasia
25 Nov 2025 //
GLOBENEWSWIRE
Transcon CNP Trial In Children With Achondroplasia Published
17 Nov 2025 //
GLOBENEWSWIRE
Ascendis Prepares To Challenge Biomarin In Achondroplasia Amid
13 Oct 2025 //
BIOSPACE
Ascendis Files MAA to EMA for TransCon CNP in Achondroplasia
09 Oct 2025 //
PHARMIWEB
Ascendis Submits MAA to EMA for TransCon CNP in Achondroplasia
08 Oct 2025 //
GLOBENEWSWIRE
Ascendis Presents Endocrinology Rare Disease Data at ASBMR 2025
02 Sep 2025 //
GLOBENEWSWIRE
FDA Approves SKYTROFA for Adult Growth Hormone Deficiency
28 Jul 2025 //
GLOBENEWSWIRE
Ascendis to Share Endocrinology Rare Disease Data at ENDO 2025
07 Jul 2025 //
GLOBENEWSWIRE
TransCon® CNP Improves Growth in Children with Achondroplasia
13 May 2025 //
GLOBENEWSWIRE
Ascendis Share Endocrinology Rare Disease Data at ESPE & ESE 2O25
05 May 2025 //
GLOBENEWSWIRE
Orsini Chosen by Ascendis to Distribute Rare Endocrine Treatment
09 Dec 2024 //
PR NEWSWIRE
Ascendis Pharma Gets US Orphan Drug Exclusivity For YORVIPATH
11 Sep 2024 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.